p-Hydroxybenzoic Acid Ameliorates Colitis by Improving the Mucosal Barrier in a Gut Microbiota-Dependent Manner

Nutrients. 2022 Dec 18;14(24):5383. doi: 10.3390/nu14245383.

Abstract

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease characterized by intestinal inflammatory cell infiltration and intestinal mucosal damage. The mechanism by which diet contributes to the pathogenesis of IBD remains largely unknown. In this study, we explored the therapeutic effect of p-hydroxybenzoic acid (HA), a phenolic acid mainly derived from dietary polyphenols in the gut, on DSS-induced colitis. HA intervention effectively relieved the dextran sulfate sodium salt (DSS)-induced colitis, reduced inflammation, and enhanced mucosal barrier function, as evidenced by an increment of goblet cell numbers and MUC2. These effects were largely dependent on the gut microbiota (GM), as antibiotics treatment substantially attenuated the improvement of colitis by HA. On the other hand, transplantation of GM from colitis mice treated with HA significantly reduced the colitis induced by DSS. Our study demonstrates that HA ameliorates DSS-induced colitis by improving the mucosal barrier in a GM-dependent manner. This study provides new dietary choices for the prevention and treatment of IBD.

Keywords: colitis; goblet cells; gut microbiota; mucosal barrier; p-hydroxybenzoic acid.

MeSH terms

  • Animals
  • Chronic Disease
  • Colitis* / chemically induced
  • Colitis* / drug therapy
  • Colitis* / pathology
  • Colon / pathology
  • Dextran Sulfate / adverse effects
  • Disease Models, Animal
  • Gastrointestinal Microbiome*
  • Inflammatory Bowel Diseases* / drug therapy
  • Inflammatory Bowel Diseases* / pathology
  • Intestinal Mucosa
  • Mice
  • Mice, Inbred C57BL

Substances

  • phenolic acid
  • Dextran Sulfate